PEPTONIC medical AB

Equities

PMED

SE0005962206

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-01-30 pm EST			5-day change	1st Jan Change
0.06 ^SEK	-.--%		-.--%	+3.45%

Apr. 17	Peptonic Medical Plans SEK61 Million Shares, Warrants Issue	MT
Apr. 15	Peptonic Medical Secures US Patent for Vaginal Yeast Infections Treatment	MT

Peptonic Medical AB Signs Distribution Agreement with Al Fotune for United Arab Emirate

November 13, 2023 at 04:00 am EST

Peptonic Medical AB (publ) announced that the company has signed a non-exclusive distribution agreement with Al Fotune Medical Equipment LLC for United Arab Emirate concerning the product VagiVital VS Pro. VagiVital VS is a self test to diagnose bacterial vaginosis and is Peptonic's best-selling product globally. VagiVital VS Pro is the professional version of the product used by gynecologists in the clinic giving the
Doctor immediate results with high precision.

Latest news about PEPTONIC medical AB

Peptonic Medical Plans SEK61 Million Shares, Warrants Issue	Apr. 17	MT
Peptonic Medical Secures US Patent for Vaginal Yeast Infections Treatment	Apr. 15	MT
Sweden’s Peptonic Medical Enters Benelux Distribution Deal for Women's Self-care Products	Apr. 02	MT
Peptonic Medical AB Strengthens Its Position in Europe Through an Exclusive Distribution Agreement for Vagivital and Vernivia in the Benelux Region	Apr. 02	CI
Peptonic Medical CFO to Depart in Mid-June	Mar. 29	MT
PEPTONIC medical AB Announces Resignation of Albert Lindgren as CFO	Mar. 28	CI
Farmasiet Extends Partnership with Peptonic Medical, Bringing VagVital's Product Portfolio to Norway	Jan. 17	CI
Peptonic Medical AB Announces Patented Apoteket Offering in 293 Apoteket Stores	Dec. 18	CI
PEPTONIC medical AB completed the acquisition of Pharmiva AB (OM : PHARM).	Nov. 20	CI
Peptonic Medical Gains on Deal with Al Fotune for VagiVital VS Pro Distribution in UAE	Nov. 13	MT
Peptonic Medical AB Signs Distribution Agreement with Al Fotune for United Arab Emirate	Nov. 13	CI
Peptonic Medical AB's Self-Test for Bacterial Vivinosis to Be Sold in over 220 Apoteket Stores	Nov. 08	CI
PEPTONIC medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-24	CI
Peptonic Medical Lands First Vaginal Self-test Order for Central American Market	23-10-19	MT
Peptonic Medical AB Receives First Order in Central America from Windsor Pharmaceuticals	23-10-19	CI
Peptonic Medical's Bacterial Vaginosis Self-test Kit to Start Selling at Walmart in US	23-10-10	MT
Pharmiva Accepts Peptonic Merger for Creation of Global Femtech Company	23-08-21	MT
PEPTONIC medical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Peptonic Medical AB Appoints Albert Lindgren as Chief Financial Officer, Effective from October 21, 2023	23-08-01	CI
Peptonic Signs License Agreement with Prima Lab Regarding Menopause Test	23-07-11	CI
Women’s Health Companies Peptonic, Pharmiva to Merge	23-06-15	MT
PEPTONIC medical AB signed a letter of intent to acquire Pharmiva AB (OM : PHARM) for SEK 15.2 million.	23-06-14	CI
Pharmiva AB (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB.	23-06-14	CI
Peptonic Medical AB Announces the Application to Patent Its Intimate Cleaner in US to Be Approved on June 20, 2023	23-06-13	CI
Sweden’s Peptonic Medical Wins Chinese Arbitration Ruling Against Yuanjia Biotechnology	23-06-08	MT

Chart PEPTONIC medical AB

Duration

Period

More charts

Company Profile

Peptonic Medical AB is a Sweden-based company active in the field of biotechnology. The Company develops estrogen-free pharmaceuticals for treatment of vaginal atrophy. The Company's main drug candidate is Vagitocin, an oxytocin-based pharmaceutical preparation for the treatment of vaginal atrophy and other menopause-related symptoms. The patented treatment is based on local, vaginal application of oxytocin to rejuvenate the vaginal mucosa. Vagitocin is to enter phase III clinical trials in Europe and the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PEPTONIC MEDICAL AB	+3.45%	8.4M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs